Download PDF
CC BY-NC-ND 4.0 · J Lab Physicians 2018; 10(01): 060-063
DOI: 10.4103/JLP.JLP_80_17
Original Article

Hematological parameters of human immunodeficiency virus positive pregnant women on antiretroviral therapy in Aminu Kano Teaching Hospital Kano, North Western Nigeria

Ibrahim Abdulqadir
Department of Haematology and Blood Transfusion, UDUTH, Sokoto, Kano, Nigeria
,
Sagir Gumel Ahmed
Department of Haematology and Blood Transfusion, Aminu Kano Teaching Hospital, Kano, Nigeria
,
Aisha Gwarzo Kuliya
Department of Haematology and Blood Transfusion, Aminu Kano Teaching Hospital, Kano, Nigeria
,
Jamilu Tukur
Department of Haematology and Blood Transfusion, Aminu Kano Teaching Hospital, Kano, Nigeria
,
Aminu Abba Yusuf
Department of Haematology and Blood Transfusion, Aminu Kano Teaching Hospital, Kano, Nigeria
,
Abubakar Umar Musa
Department of Haematology and Blood Transfusion, UDUTH, Sokoto, Kano, Nigeria
› Author Affiliations Financial support and sponsorship: Nil
› Further Information
Also available at
  PDF Download Permissions and Reprints

Abstract

CONTEXT: Human immunodeficiency virus (HIV) scourge continues to affect young women within the reproductive age group and pregnancy is a recognized indication for the use antiretroviral (ARV) drugs among HIV-positive women.

AIMS: The aim is to determine the combined effect of pregnancy, HIV and ARV drugs on the hematological parameters of the pregnant women.

SETTINGS AND DESIGN: This was a comparative cross-sectional study conducted among 70 each of HIV-positive and negative pregnant women.

SUBJECTS AND METHODS: Bio-demographic and clinical data were extracted from the client folder and 4 ml of blood sample was obtained from each participant. Full blood count was generated using Swelab automatic hematology analyzer while reticulocyte count and erythrocyte sedimentation rate (ESR) were conducted manually.

STATISTICAL ANALYSIS USED: Data analysis was performed using SPSS version software 16 while P < 0.05 was considered statistically significant.

RESULTS: Pregnant women with HIV had statistically significant lower hematocrit and white blood cell (WBC) and higher ESR than pregnant women without HIV (P < 0.000). There was no statistically significant difference between the two groups in terms of platelet and reticulocyte (P > 0.05). However, among HIV positive pregnant women, those with CD4 count <350/μL had statistically significant lower WBC and lymphocyte count than those with CD4 count ≥350/μL (P < 0.05), whereas, those on zidovudine (AZT)-containing treatment had statistically significant lower hematocrit and higher mean cell volume than those on non-AZT-containing treatment (P < 0.05), but there was no statistically significant difference in any of the hematological parameters (P > 0.050) between women on first- and second-line ARV regimens.

CONCLUSIONS: There is a significant difference in terms of hematological parameters between HIV-positive and HIV-negative pregnant women in this environment.

Key words

Antiretroviral drugs - hematological parameters - human immunodeficiency virus - Kano - pregnant women


Publication History

Received: 27 April 2017

Accepted: 11 August 2017

Article published online:
19 February 2020

© 2018.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Nigerian National HIV/AIDS Prevention Plan (2014-2015). Federal Ministry of Health, Abuja, Nigeria; 2013.
  • 2 Integrated National Guidelines for HIV Prevention, Treatment and Care. National AIDS/STIs ontrol Programme. Federal Ministry of Health, Abuja, Nigeria; 2014.
  • 3 Chandra S, Tripathi AK, Mishra S, Amzarul M, Vaish AK. Physiological changes in hematological parameters during pregnancy. Indian J Haematol Blood Transfus 2012;28:144-6.
  • 4 Chaudhari SJ, Bodat RK. Is there any difference in haematological parameters in pregnant and non-pregnant women? Natl J Community Med 2015;6:429-32.
  • 5 Dikshit B, Wanchu A, Sachdeva RK, Sharma A, Das R. Profile of hematological abnormalities of Indian HIV infected individuals. BMC Blood Disord 2009;9:5.
  • 6 Erhabor O, Ejele OA, Nwauche CA, Buseri FI. Some haematological parameters in human immunodeficiency virus (HIV) infected Africans: The Nigerian perspective. Niger J Med 2005;14:33-8.
  • 7 Oshikoya KA, Lawal S, Oreagba IA, Awodele O, Olayemi SO, Iroha EO, et al. Adverse events in HIV infected children on antiretroviral therapy at a teaching hospital in Lagos, Nigeria: A retrospective study. Adv Pharmacoepidemiol Drug Saf 2012;1:117.
  • 8 ARROW Trial team, Kekitiinwa A, Cook A, Nathoo K, Mugyenyi P, Nahirya-Ntege P, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): A 5-year open-label randomised factorial trial. Lancet 2013;381:1391-403.
  • 9 Chukwuyenum PI, Jocobs J, Ngozi RI, Lawrence OE. Changes in haematological indices in normal pregnancy. Physiol J 2013. Doi: 10.1155/2013/283814.
  • 10 Akinbami A, Oshinaike O, Adeyemo T, Adediran A, Dosunmu O, Dada M, et al. Haematological abnormalities in treatment naïve HIV patients. Infect Dis Res Treat 2010;3:45-9.
  • 11 Adane A, Desta K, Bezabih A, Gashaye A, Kassa D. HIV-associated anaemia before and after initiation of antiretroviral therapy at Art Centre of Minilik II Hospital, Addis Ababa, Ethiopia. Ethiop Med J 2012;50:13-21.
  • 12 Borges-Almeida E, Milanez HM, Vilela MM, Cunha FG, Abramczuk BM, Reis-Alves SC, et al. The impact of maternal HIV infection on cord blood lymphocyte subsets and cytokine profile in exposed non-infected newborns. BMC Infect Dis 2011;11:38.
  • 13 Mwinga K, Vermund SH, Chen YQ, Mwatha A, Read JS, Uransa W, et al. Selected haematological and biochemical measurements in African HIV infected and uninfected pregnant women and their infants: The HIV prevention trial network 024 protocol. BMC Paediatr 2009;9:49.
  • 14 Munyazesa E, Emile I, Mutimura E, Hoover DR, Shi Q, McGinn AP, et al. Assessment of haematological parameters in HIV-infected and uninfected Rwandan women: A cross-sectional study. BMJ Open 2012;2. pii: E001600.
  • 15 Volberding PA, Levine AM, Dieterich D, Mildvan D, Mitsuyasu R, Saag M; Anemia in HIV Working Group. Anemia in HIV infection: Clinical impact and evidence-based management strategies. Clin Infect Dis 2004;38:1454-63.
  • 16 Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: Collaborative analysis of prospective cohort studies. Antivir Ther 2008;13:959-67.
  • 17 Sharma SK. Zidovudine-induced anaemia in HIV/AIDS. Indian J Med Res 2010;132:359-61.
  • 18 Shah I. Adverse effects of antiretroviral therapy in HIV-1 infected children. J Trop Pediatr 2006;52:244-8.
  • 19 Lane HC. Pathogenesis of HIV infection: Total CD4+ T-cell pool, immune activation, and inflammation. Top HIV Med 2010;18:2-6.
  • 20 Firnhaber C, Smeaton L, Saukila N, Flanigan T, Gangakhedkar R, Kumwenda J, et al. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis 2010;14:e1088-92.
  • 21 Moore DA, Sullivan A, Hilstead P, Gazzard BG. A retrospective study of neutropenia in HIV disease. Int J STD AIDS 2000;11:8-14.